Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.

Tuberculosis (TB) is one of the world's oldest and deadliest diseases, killing a person every 20 s. InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis, is the target of the frontline antitubercular drug isoniazid (INH). Compounds that directly target InhA and do not require activation by mycobacterial catalase peroxidase KatG are promising candidates for treating infections caused by INH resistant strains. The application of the encoded library technology (ELT) to the discovery of direct InhA inhibitors yielded compound 7 endowed with good enzymatic potency but with low antitubercular potency. This work reports the hit identification, the selected strategy for potency optimization, the structure-activity relationships of a hundred analogues synthesized, and the results of the in vivo efficacy studies performed with the lead compound 65.

[1]  Rosella Centis,et al.  INVITED REVIEW SERIES: TUBERCULOSIS , 2010 .

[2]  Yun Ding,et al.  Discovery of Potent and Selective Inhibitors for ADAMTS-4 through DNA-Encoded Library Technology (ELT). , 2015, ACS medicinal chemistry letters.

[3]  O. Kon,et al.  Multidrug- and extensively drug-resistant tuberculosis: an emerging threat , 2009, European Respiratory Review.

[4]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[5]  W. Jacobs,et al.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.

[6]  S. Cole,et al.  Synthesis and antimycobacterial activity of 2,1'-dihydropyridomycins. , 2013, ACS medicinal chemistry letters.

[7]  Peter J Tonge,et al.  Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds. , 2012, Current topics in medicinal chemistry.

[8]  Z. Memish,et al.  Epidemiology of Antituberculosis Drug Resistance in Saudi Arabia: Findings of the First National Survey , 2013, Antimicrobial Agents and Chemotherapy.

[9]  Gordon L. Amidon,et al.  Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs , 2009, The AAPS Journal.

[10]  K. Kam,et al.  Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance , 2009, The Lancet.

[11]  P. Bamborough,et al.  5-Aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[12]  J S Blanchard,et al.  Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. , 2002, Current pharmaceutical biotechnology.

[13]  C. Dye,et al.  Worldwide incidence of multidrug-resistant tuberculosis. , 2002, The Journal of infectious diseases.

[14]  Baoguang Zhao,et al.  Design, synthesis and selection of DNA-encoded small-molecule libraries. , 2009, Nature chemical biology.

[15]  Q. You,et al.  Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis. , 2010, Mini reviews in medicinal chemistry.

[16]  James C. Sacchettini,et al.  Inactivation of the inhA-Encoded Fatty Acid Synthase II (FASII) Enoyl-Acyl Carrier Protein Reductase Induces Accumulation of the FASI End Products and Cell Lysis of Mycobacterium smegmatis , 2000, Journal of bacteriology.

[17]  M. Donald Cave,et al.  Population Genetics Study of Isoniazid Resistance Mutations and Evolution of Multidrug-Resistant Mycobacterium tuberculosis , 2006, Antimicrobial Agents and Chemotherapy.

[18]  Siva Lavu,et al.  Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3. , 2013, Journal of medicinal chemistry.

[19]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[20]  J. Höchel,et al.  Improving the ex vivo stability of drug ester compounds in rat and dog serum: inhibition of the specific esterases and implications on their identity. , 2010, Journal of pharmaceutical and biomedical analysis.

[21]  J C Sacchettini,et al.  Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. , 1995, Biochemistry.

[22]  S. Parikh,et al.  Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. , 2000, Biochemistry.

[23]  G. Bai,et al.  Worldwide Emergence of Extensively Drug-resistant Tuberculosis , 2007, Emerging infectious diseases.

[24]  I. Kuntz,et al.  The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  David Alland,et al.  Targeting Tuberculosis and Malaria through Inhibition of Enoyl Reductase , 2003, Journal of Biological Chemistry.

[26]  M. Espinal,et al.  The global situation of MDR-TB. , 2003, Tuberculosis.

[27]  C. Vilchèze,et al.  Crystal Structure of the Mycobacterium tuberculosis Enoyl-ACP Reductase, InhA, in Complex with NAD+ and a C16 Fatty Acyl Substrate* , 1999, The Journal of Biological Chemistry.

[28]  Matthew W Vetting,et al.  Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid , 2006, Nature Structural &Molecular Biology.

[29]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[30]  D. Zerbib,et al.  The Mycobacterium Tuberculosis FAS-II Dehydratases and Methyltransferases Define the Specificity of the Mycolic Acid Elongation Complexes , 2011, PloS one.

[31]  Christopher W. Murray,et al.  Assessing the lipophilicity of fragments and early hits , 2011, J. Comput. Aided Mol. Des..

[32]  J. Sacchettini,et al.  Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis , 1995, Science.

[33]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[34]  P. Cardona,et al.  Fast Standardized Therapeutic-Efficacy Assay for Drug Discovery against Tuberculosis , 2010, Antimicrobial Agents and Chemotherapy.

[35]  P. Farmer,et al.  Redefining MDR-TB transmission 'hot spots'. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[36]  Hongfeng Deng,et al.  Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT). , 2012, Journal of medicinal chemistry.

[37]  Hans Lennernäs,et al.  The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension , 2005, The Journal of pharmacy and pharmacology.

[38]  T. Scior,et al.  Isoniazid is not a lead compound for its pyridyl ring derivatives, isonicotinoyl amides, hydrazides, and hydrazones: a critical review. , 2006, Current medicinal chemistry.

[39]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.